Volume 1 Number 2

Editorial
16
Introduction and thoughts on the second issue of EuroIntervention

EuroInterv.2005;2:121

17
Coin of the realm: do only randomized trials count or is ART okay?

EuroInterv.2005;2:122

18
The Endeavor Stent System: will it be the next kid in the block? Numero uno, first among equals or equal?

EuroInterv.2005;2:123-124

19
Blowing against the wind?

EuroInterv.2005;2:125-127

20
Beyond crossing a chronic total occlusion. Are the drug-eluting stents the solution for this old problem?

EuroInterv.2005;2:129-131

Working Group 10 column
21
Launching a new journal dedicated to interventional cardiology is a great challenge.

EuroInterv.2005;2:133

22
Training in interventional cardiology in Europe: how to move from chaos to rational common programs?

EuroInterv.2005;2:135-137

Special article
23
EuroPCR highlights 2005

EuroInterv.2005;2:139-144

24
EuroIntervention: a politician's view

EuroInterv.2005;2:145-146

Clinical research
25
Arterial Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novocoronary artery lesions

EuroInterv.2005;2:147-156

26
First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novonative coronary artery lesions: Endeavor I Trial

EuroInterv.2005;2:157-164

27
One-year clinical outcome of various doses and pharmacokinetic release of paclitaxel eluted from an erodable polymer - Insights from the Paclitaxel In-Stent Controlled Elution Study (PISCES)

EuroInterv.2005;2:165-172

28
Immunosuppressive oral prednisone after percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS-2/MVD study

EuroInterv.2005;2:173-180

29
Drug-eluting stent-supported percutaneous coronary intervention in high risk patients refused cardiac surgery

EuroInterv.2005;2:181-185

30
Early and late results of percutaneous revascularization in patients with ischemic cardiomyopathy and decreased left ventricular ejection fraction. (Revascularisation in Heart Failure Trial, REHEAT Registry)

EuroInterv.2005;2:186-192

31
Drug-eluting stent implantation for chronic total occlusions: comparison between the Sirolimus- and Paclitaxel-eluting stent

EuroInterv.2005;2:193-197

32
Primary stenting for left-main shock syndrome

EuroInterv.2005;2:198-203

33
150 microgram intracoronary adenosine bolus for accurate fractional flow reserve assessment of angiographically intermediate coronary stenosis

EuroInterv.2005;2:204-207

34
Preprocedural creatinine clearance and long term survivalafter successful coronary stenting

EuroInterv.2005;2:208-213

35
CMR assessment of AMI patients treated by PCI shows delays in myocardial reperfusion despite initial achievement of TIMI 3 flow

EuroInterv.2005;2:214-218

36
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease

EuroInterv.2005;2:219-227

Experimental research
37
The effect of variable release kinetics on Paclitaxel efficacy from a drug eluting stent in a porcine model

EuroInterv.2005;2:228-235

38
Inhibition of intimal hyperplasia by the tetracycline derived MMP inhibitor doxycycline in vein graft disease in vitro and in vivo

EuroInterv.2005;2:236-243

New devices
39
Assessment of stent dimensions with a novel intracoronary balloon-based system: comparative study versus intravascular ultrasound and quantitative coronary angiography. The CAMUS - Coronary Angioplasty Metricath vs. UltraSound Trial

EuroInterv.2005;2:244-251

Volume 1 Number 2 has been released thanks to the support of the following partners:
  • Abbott Vascular Devices
  • Boston Scientific
  • Conor Medsystems
  • Cordis, a Johnson & Johnson company
  • Medtronic
  • Mentice AB
  • Siemens Medical
  • Terumo

Online ISSN 1969-6213 - Print ISSN 1774-024X